That's interesting. You referenced the number of biopsies yourself and also speculated that it wasn't feasible to do them all. I was reiterating the same concerns. In fact you knew the exact number of biopsies which was news to me. What's your source? Oh I guess it was publicly available.
Heres the publicly available facts. In the COBRA trial if an image taken bu cu64 was put next to an Illucix image and lesions were not seen on the Illucix image they were not accepted as reliable without further proof. Furthermore it's a matter of interpretation. If the FDA forces Clarity to call all lesions identified by cu64 false positives if not seen by subsequent scans by competitor products..or by the patient then having a follow up biopsy (from memory one patient had around 90 previously unidentified lesions) ... I will call it FDA disallowing a head to head comparison.. you can call it what you like... or pretend it didn't happen... or that it doesn't matter. Frankly I don't care. End of discussion.
CU6 Price at posting:
$2.83 Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)